Search

Displaying results 2661 - 2670 of 10000 in total
  1. Drug

    Dexmedetomidine

    go.drugbank.com/drugs/DB00633
    ApprovedInvestigationalVet approved

    An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.

  2. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    Centanafadine is a reuptake inhibitor at the norepinephrine, dopamine, and serotonin transporters and a central nervous system stimulant. … reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment.

  3. Drug

    VIR201

    go.drugbank.com/drugs/DB05110
    Experimental

    is an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.

  4. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    There has been a case of barbexaclone abuse due to the amphetamine like properties of propylhexedrine, although the comparative abuse potential is much lower than amphetamine. … Several reports from Spanish and Italian literature suggest that barbexaclone is at least as effective as phenobarbital in adults and children, while being better tolerated and having less sedative properties

  5. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD. … Phenserine is a next generation acetylcholinesterase (AChE) inhibitor indicated for the treatment of AD.

  6. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity

    Categories: MATE 1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  7. Drug

    Tenofovir

    go.drugbank.com/drugs/DB14126
    Investigational

    [A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. … Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate.

  8. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    [L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment … [A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes.

  9. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    The drug made it to phase III trials before abandoned due to increased stroke. … Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

  10. Drug

    DA-697b

    go.drugbank.com/drugs/DB06001
    Experimental

    DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.